Co-incubation of Reozalimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Reozalimab was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 0.728 nM.

Reozalimab bound to huPD-L1-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Reozalimab bound to huPD-L1-CHO-K cells, and the EC50 was 2.237 nM.

Reozalimab bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Reozalimab bound to huPD-1-Jurkat cells, and the EC50 was 0.990 nM.

Reozalimab bound to PD-L1 protein, and then rebounded to secondary antibodies(Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Reozalimab bound to huPD-L1-Fc, and the EC50 was 0.015 nM.

Reozalimab bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Reozalimab bound to huPD-1-His, and the EC50 was 0.004 nM.

The purity of Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab) is 95.07%, determined by SEC-HPLC.

Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The detected weight of Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab) is 143.56 kDa.